Apr 12, 2021
Critically, the University’s ability to do deep analysis of miRNA content enabled VivaZome to link exosome content to biological activity and so to potential clinical application.
Professor Hill, Associate Provost of Research and Industry Engagement at La Trobe said: “It is exciting to extend our CRC-Project into a new research relationship and to use our expertise in exosome analytics and characterisations to contribute to the success of VivaZome’s development program. We look forward to working with VivaZome and their national and international collaborators.”
VivaZome‘s Chief Executive Officer, Dr David Haylock, said: “VivaZome is delighted to enter in to this new, post-CRC-P partnership with La Trobe and to extend its productive relationship with Professor Hill and his research team. As VivaZome broadens its portfolio of activity to encompass ischaemia, fibrotic diseases and neurological disorders, La Trobe’s world-class capability will provide a st